HK Stock Market Move | YIDU TECH (02158) rose more than 12% as Huawei officially formed a healthcare team. Citigroup is optimistic about AI improving healthcare operating efficiency.

YIDU TECH (02158) rose more than 12%, as of the time of publication, it rose 12.55% to HK$7.89, with a trading volume of HK$58.18 million. On the news front, Huawei has officially formed a medical health legion, focusing on building an AI-assisted diagnostic solution system and promoting the application of medical large models in clinical scenarios. Tianfeng suggests focusing on directions with high-quality data, scarce application scenarios, and multimodal integrated data, such as AI + health management, AI + detection diagnosis treatment, AI + doctor digital platform, AI + medical informationization, and companies related to AI + drug development. It is worth mentioning that YIDU TECH and Huawei will launch a joint innovation of large models in 2023, based on the Ascend AI hardware and software, the two sides have created a medical large model all-in-one machine, providing customers with an out-of-the-box AI full-stack solution. In addition, YIDU TECH announced this morning that a new member has been added to the friends circle of the Yidu AI middle platform. Shanghai Pulmonary Hospital has not only completed the localized deployment of DeepSeek but also will access the Yidu AI middle platform, teaming up with YIDU TECH's "AI medical brain" YiduCore to enhance medical management efficiency. Citigroup previously stated that in the short term, AI technology can help companies reduce employee costs by improving operational efficiency. In the medium to long term, as technology matures and application deepens, the market will usher in a prosperous golden age. With its independently developed AI technology and industry accumulation, YIDU TECH is expected to fully benefit from this trend. The bank maintains a "buy" rating on YIDU TECH and raises its target price from HK$8 to HK$12.